|
|
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Cell Death and Cancer Therapy (November 15, 2015)
Innovations to Speed Drug Development (October 15, 2015)
Progress in Lung Cancer (May 15, 2015)
Targeting RAS-Driven Cancers (April 15, 2015)
2015 CCR Focus Sections
Cell Death and Cancer Therapy
November 15, 2015
Guest Editor: Anthony Letai, 21 (22) : 5013–5056
How Do Cancer Cells Die?
Susan E. Bates
Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
Anthony Letai
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Christopher J. Gibson and Matthew S. Davids
Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Simone Fulda
Autophagy, Metabolism, and Cancer
Eileen White, Janice M. Mehnert, and Chang S. Chan
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martínez-Lostao, Alberto Anel, and Julián Pardo
MInnovations to Speed Drug Development
October 15, 2015
Guest Editors: Eric H. Rubin and Patricia M. LoRusso, 21 (20) : 4526–4568
On Innovating and Inspiring the Clinical Trial Enterprise
Susan E. Bates
Advancing Clinical Trials to Streamline Drug Development
Susan E. Bates, Donald A. Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M. LoRusso, and Eric H. Rubin
Next-Generation Sequencing to Guide Clinical Trials
Lillian L. Siu, Barbara A. Conley, Scott Boerner, and Patricia M. LoRusso
Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
Marc R. Theoret, Lee H. Pai-Scherf, Meredith K. Chuk, Tatiana M. Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G. Kluetz, Patricia Keegan, and Richard Pazdur
Failures in Phase III: Causes and Consequences
Bostjan Seruga, Alberto Ocana, Eitan Amir, and Ian F. Tannock
The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases
David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John-Peter Bradford, Joan H. Schiller, and Razelle Kurzrock
Progress in Lung Cancer
May 15, 2015
Guest Editors: Roy S. Herbst and Katerina Politi, 21 (10) : 2212–2262
Quit Early, Quit Often
Susan E. Bates
Lung Cancer in the Era of Precision Medicine
Katerina Politi and Roy S. Herbst
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Gregory J. Riely and Helena A. Yu
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin
Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger
Targeting RAS-Driven Cancers
April 15, 2015
Guest Editor: Frank McCormick, 21 (8) : 1796–1834
Targeting RAS: The Elusive Prize
Susan E. Bates
KRAS as a Therapeutic Target
Frank McCormick
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Julian Downward
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Kendra Marcus and Carla Matto
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox, Channing J. Der, and Mark R. Philips
Metabolic Dependencies in RAS-Driven Cancers
Alec C. Kimmelman
Clinical Cancer Research Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9354 | E-mail: ccr@aacr.org